Gallbladder cancer during pregnancy treated with surgery and adjuvant gemcitabine: A case report and review of the literature

A. Diciolla1,2, M. Gianoni3, M. Fleury1,2, P. Szturz1,2, N. Demartines2,4, S. Peters1,2, R. Duran2,5, D. Desseauve2,6, Monnat A. Panchaud7, F. Fasquelle2,8 and A. Digklia1,2*

1Département d’Oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, 2Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland, 3University of Lausanne (UNIL) et Service de Gynécologie, CHUV, Lausanne, Switzerland, 4Department of Visceral Surgery, CHUV, Lausanne, Switzerland, 5Department of Radiology and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland, 6Women-Mother-Child Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, 7Service of Pharmacy Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, 8Institut Universitaire de Pathologie, Pathologie Clinique, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

Background: Gallbladder cancer (GBC) represents the most common biliary tract cancer. Prognosis remains poor with 5-year overall survival rates less than 5% in advanced stages. GBCs are diagnosed more frequently in women, supposedly due to endocrine factors.

Case: A 35-year-old woman, diagnosed with a non-metastatic GBC in the 22nd week of gestation, underwent a complete surgical resection 5 weeks later. Adjuvant gemcitabine was administered without complications, temporarily discontinued in the 32nd week to allow childbirth. The patient was disease-free for more than 3 years with ongoing remission at the last visit in July 2022. During the follow-up period, the child had no developmental, cognitive, or other health issues.

Conclusion: Malignant tumors occur in about 0.1% of pregnant women, many are treated with chemotherapy. In oncology, the need to deliver optimal treatment in these patients represents a major concern. Both surgery and adjuvant chemotherapy of locally advanced GBC can be performed safely, with certain considerations, in the second trimester of pregnancy.

KEYWORDS
gallbladder cancer, chemotherapy, pregnancy, gemcitabine, biliary tract cancer
Introduction

Gallbladder cancer (GBC) is considered a highly fatal hepatobiliary malignancy due to its poor 5-year survival rate of 0-12% and median overall survival (OS) of less than 6 months in untreated patients (1). Worldwide, there is prominent geographic variability in GBC incidence (2), which can be illustrated by its distribution on the American continent, with high rates seen in South American countries (for example incidence ≥1.6 per 100,000 individuals in Chile) strongly contrasting with the US 0.56-0.82 low-incidence. While socioeconomic factors explain these disparities (i.e. delayed access to cholecystectomy for gallstones (3)) the strong gender difference in the distribution of the disease does not. Even in low-incidence countries, women are affected 2-3 times more frequently than men (2). The association of GBC with the female gender has been hypothesized to be influenced by estrogens leading to an increase in the supersaturation of bile cholesterol, being therefore potentially involved in the pathogenesis of GBC mediated by gallstones (4). This over-representation of female gender, unfortunately, increases the risk for diagnoses during pregnancy. In the absence of metastasis, surgery and adjuvant chemotherapy are the cornerstones of treatment, but exposure during pregnancy to molecules described as deleterious to the fetus (5, 6) may lead to a decision to terminate the pregnancy or forego treatment leading to dramatic consequences (7). In order to provide data for this critical decision making, the case presented here is a pregnant patient diagnosed with GBC and treated by surgery and adjuvant gemcitabine chemotherapy during pregnancy with a follow-up of more than 3 years.

Case description

In February 2019, a 35-year-old African woman in the 22nd week of gestation presented with acute biliary pancreatitis due to gallbladder polyps. Two weeks later, the patient underwent a cholecystectomy by laparoscopy without maternal nor fetal complications. The histopathological examination revealed an incidental gallbladder carcinoma classified as pT2a pNx L0 V0 G2 R0 according to the American Joint Committee on Cancer staging system (8th edition). Additional examinations were therefore carried out, including a non-contrast magnetic resonance imaging (MRI) two weeks after the first surgery (Figure 1). Serum tumor markers including carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) were within normal limits (< 2 kU/L and 1.8 µg/L, respectively) and the expression of MMR proteins (MLH1, MSH2, MSH2 and PM2) and HER-2 by immunohistochemistry in tumor tissue were normal. After a discussion with the patient, particular care was dedicated to maintain the pregnancy that the patient wished to preserve. Following multidisciplinary tumor board discussion, the patient underwent an open liver bi-segmentectomy of segments IVb and V showing two retro-portal lymph node metastases of GBC with one of them presenting capsular effraction. The tumor was classified pT2a pN1(2/8), grade 2, without lymphovascular invasion, stage IIIB. No postoperative complications were observed. Fetal growth, liquor volume, and end-diastolic flow on ultrasound at 26 weeks were normal.

After an explanation about the benefit-risk balance of adding chemotherapy treatment, the patient began adjuvant gemcitabine and the pregnancy was carried on until 32 weeks of gestation. Because of the risk of preterm delivery, the patient received corticosteroids for fetal lung maturation before hepatic surgery. Between the 28th and 32nd week of pregnancy, the patient was treated with one cycle of gemcitabine chemotherapy (1000 mg/m2 on days 1 and 8 of a 21-day cycle) with no grade 2 or more adverse events. Chemotherapy was administered on an inpatient basis to facilitate fetal monitoring, and no adverse fetal effects were observed. The treatment was interrupted 2 weeks prior to the planned birth induction at 32 weeks. Because of breech position at admission, the patient underwent a cesarean section. The newborn girl had a birth weight of 1,570 g, a length of 41 cm, and a head circumference of 28.5 cm (all values in the normal range for gestational age). The Apgar score was 7/9/9 at 1, 5 and 10 minutes respectively. The placenta showed no signs of metastatic spread. A complete neonatal evaluation revealed no gross malformations, neurological or cardio-circulatory abnormalities, infection, or bone marrow suppression. Peripheral blood count was as follows: leukocytes 16.5x10^9/L, hemoglobin 17.3 g/dL, and platelets 417,000/µL. Supplemental enteral nutrition by nasogastric tube was required for the first 6 days. The infant developed indirect hyperbilirubinemia with jaundice and hemoglobin level of 13.2 g/dL on day 14, requiring iron infusion.

The infant was discharged from the hospital in very good general condition one month after the birth. Her weight was 2,380 g (below the third percentile), height 45 cm (below the third percentile), and head circumference 31 cm (below the third percentile). Pediatric follow-up at 8 and 18 months of corrected age confirmed normal physical and neurological development. At the latter visit, the infant’s weight was 13 kg (above the 97th percentile), her height 87 cm (above the 97th percentile), and head circumference 48.5 cm (between the 75th and 90th percentile).

At 6 weeks postpartum, chemotherapy with gemcitabine was resumed using the same dosing schedule as during the pregnancy, in combination with capecitabine at 1500 mg orally twice a day for the first two weeks of every 3-week cycle and a total of 6 months were administered.

After finishing chemotherapy, the first follow-up imaging by abdominal MRI and thoraco-abdominal computed tomography (CT) was performed in October 2019, revealing no signs of local recurrence or distant metastases (Figures 1C-F). Further oncologic surveillance included clinical, laboratory (CEA, CA 19-9) and radiological monitoring. In this respect, the patient
had a lung CT and abdominal MRI every three months in the first two years after the intervention, then the intervals were increased to every six months. This patient has been disease-free for more than 3 years with ongoing remission at the last visit in February 2022. Figure 2 summarizes the disease course in our patient.

Discussion

There is an increasing number of cancers discovered during pregnancies, as shown by several contemporary epidemiological studies (8). Concerning surgery, it can be safely carried out at any time during pregnancy. However, a higher risk of miscarriage has been reported in the first trimester. Also, the risk of small for gestational age fetuses has been reported when a pregnant patient undergoes a long abdominal procedure during pregnancy. Moreover, major abdominal and pelvic surgery is associated with increased morbidity and pregnancy complications, like premature delivery, throughout the whole gestation period. Therefore, watchful waiting policy can also be considered. Nevertheless, when the patient is at high risk for torsion (usually at gestational weeks 8-16), rupture infarction, or acute abdomen, surgical management is indicated (9).
If a choice is possible, the second trimester is preferable for surgery. Nevertheless, surgery should never be postponed if deemed to be crucial for patient care management (10).

Given the propensity of GBC to spread to the regional lymph nodes and peritoneal surface, staging laparoscopy can help avoid unnecessary laparotomy in 38-62% of patients. Based on the aggressivity of the disease, staging laparoscopy is recommended in all cases of suspected or proven GBC. As a result, only 25% of patients will undergo potentially curative surgery and only 16% will survive more than 5 years (10). After curative surgery for biliary tract cancers, the ideal adjuvant chemotherapy has not been established but most centers used adjuvant capecitabine for 6 months based on the BILCAP phase III study. In this trial, although no significant difference in OS was observed, in an unadjusted intent-to-treat (ITT) analysis, a per-protocol analysis revealed significant results (median, 53 months in the chemotherapy arm vs. 36 months in the observation group; \( p=0.028 \)). Furthermore, a pre-specified intent-to-treat analysis adjusted for nodal status, disease grade and sex also showed significant difference between the two groups. In the present case, due to the aggressivity of the disease, combination of gemcitabine/capecitabine was chosen.

Since capecitabine cross the placenta and have been shown to be teratogenic and embryolethal, it was decided to start with gemcitabine during pregnancy and add capecitabine after delivery. Furthermore, due to low-risk emetic risk induced by gemcitabine, no prophylactic anti-emetic therapy was prescribed in this case.

Providing the maximum benefit to the mother through early delivery and aggressive chemotherapy against aggressive form of cancers has clear drawbacks related to the induction of premature delivery and possible side effects of chemotherapy on the fetus, such as growth restriction, and anemia secondary to bone marrow suppression. Currently, it is widely accepted that chemotherapy can be safely administered during the second and third trimesters, always with close monitoring of the mother and fetus. The blood placenta barrier limits fetal exposure to cytotoxic drugs with a different transplacental capacity for various drugs (11). Furthermore, placental dissemination, as a rare manifestation of cancer in pregnancy, comprises in the first place a direct infiltration of placental tissue and less probably the presence of malignant cells in the intervillous space corresponding to invasion in the maternal vascular compartment. Owing to the anatomical and immune barrier of the placenta, fetal metastases are even less common (12).

To our knowledge, there are no studies describing whether the human placenta is an effective barrier to gemcitabine but only case reports (Table 1). The treatment was aligned with the assessment done by Briggs (18), considering: (a) gemcitabine molecular weight and negligible plasma protein binding (b) animal data (6) (c) trimester of pregnancy (avoiding first trimester which represents organogenesis) (d) very short plasma elimination half-life reducing the amount reaching the embryo–fetus allowing gemcitabine use from the second trimester of pregnancy.

Recently, a descriptive cohort study of 1,170 pregnant cancer patients (39% with breast cancer) aimed at analyzing changes over time in cancer, obstetric, and neonatal outcomes. The authors observed an increase in the use of chemotherapy during pregnancy, in parallel with an increase in live births, and a reduction in iatrogenic preterm deliveries, encouraging the management of these patients in high obstetric care units (19). Before starting any oncological treatment, a fetal examination with ultrasound should be performed after 8th week to exclude pre-existing abnormalities, because exposure to cytotoxic agents in the first trimester can interfere with fetal organogenesis, resulting in an increased risk of miscarriages and congenital malformations. If there is an urgent need to start chemotherapy during pregnancy, the option of preterm labor to avoid any delay in treatment initiation should be carefully discussed with the patient.

The present case represents the first description in the literature of gemcitabine administration in a pregnant woman.
| First author, year | Diagnosis | Patient age [years] | Gestational age at treatment initiation [weeks] | Initial disease stage | Initial treatment intent | Chemotherapy Doses et durées d’exposition | Response to gemcitabine-based treatment | Outcome of the infant |
|-------------------|-----------|---------------------|-----------------------------------------------|-----------------------|-------------------------|------------------------------------------|--------------------------------------|----------------------|
| Kim, 2008 (13)    | metastatic pulmonary adenocarcinoma + brain met | 35 | 9-22 | stage IV with brain metastases | palliative | 1st line: docetaxel and cisplatin (days 1 and 8) every 3 weeks | progression after 1 cycle | About 2 months after the last dose, her pregnancy was diagnosed. A cesarean section was performed at 33 weeks to deliver a normal, 1490 g female infant (normal karyotype 46, XX) with Apgar scores of 8, 9, and 10 at 1, 5, and 10 minutes, respectively, and normal blood counts. An extensive examination of the infant failed to find any abnormalities. She was developing normally at 10 months of age |
| Gurumurthy, 2009 (14) | non-small-cell lung cancer | 38 | 25 | stage IV with bilateral lung metastases | palliative | gemcitabine (1000 mg/m2 on day 1 and 8) and carboplatin AUC 5 (day 1) | partial remission of the hepatic lesion. no signs of recurrent disease in the region of previous surgery. However, a slight progression of a previously very small pelvic metastasis was reported. Confirming our clinical impression during the previous weeks, bone metastases of the frontotemporal cranium, ribs, and ilium were revealed by bone scintigraphy and cranial CT. Abdominal MRI confirmed progressive disease in the liver and bone metastases with large soft tissue components. |
| Lubner, 2011 (15) | pancreatic adenocarcinoma | 37 | 24-31 | Stage III | curative | gemcitabine (1000 mg/m2) beginning her 24th week of pregnancy, until her 31st week. | elective cesarean section at 28 4/7 weeks to a baby girl with Apgar scores of 7 and 9 at 1 and 5 minutes, respectively. The infant had multiple complications secondary to prematurity. The authors speculated that two unusual features, chronic lung disease and excessive secretions from her lungs, might have been related to either the chemotherapy or an effect of the malignancy itself. At 8 months of age, the infant had been weaned off of oxygen therapy and her neurodevelopment was age-appropriate |
| Wiesweg, 2014 (16) | Metastatic cholangiocellular adenocarcinoma | 38 | 18 | | | | At 35 weeks, labor was induced to deliver a normal male infant with blood counts within normal limits. He was developing normally with a functionally intact immune system at nearly 2 years of age. The mother died 12 months after diagnosis (relapse was diagnosed 2 weeks after delivery, and 6 weeks off chemotherapy) |
| Steinberg, 2020 (17) | Hodgkin lymphoma | | | | | | 35 + 0, delivering a healthy female infant, Apgar 9/10/10, birth weight 1,840 g (20th percentile), length 41 cm (20th percentile), and head circumference 30 cm (30th percentile). The baby initially showed labored breathing with retractions but did not require supplemental oxygen, breathing spontaneously at all times. Examination revealed no evidence of gross malformations, neurological or cardiocirculatory abnormalities, and infection or bone marrow suppression (leukocytes 6.85/mL, hemoglobin 14.5 g/dL, and platelets 320/mL). Supplemental enteral feeding via nasogastric tube was necessary for 10 days. The baby was discharged from the hospital in very good general condition 1 month after her birth. Weight was 2,340 g (< third percentile), height 42 cm (< third percentile), and head circumference 31 cm (< third percentile). |

(Continued)
with biliary tract cancer, successfully treated with surgery and adjuvant chemotherapy during gestation period, leading to a disease-free interval of more than 3 years. Table 1 summarizes other case reports describing the results of gemcitabine-based chemotherapy during pregnancy. In addition, no acute or late side effects of chemotherapy were observed in the infant during 3-year follow-up.

**Conclusion**

A multidisciplinary approach involving surgeons, obstetricians, neonatologists and oncologists is required. In addition, shared decision-making with the patient and family members is indispensable in the management of cancer diagnosed during pregnancy. In addition, the maternal benefit of gemcitabine seems to outweigh the unknown fetal risk.

The present case report demonstrates that surgery of gallbladder cancer followed by adjuvant chemotherapy with gemcitabine can be carried out safely and effectively in the gestational period.

**Ethics statement**

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**Author contributions**

AD (11th author), ND, PS contributed to the conception and design of the study. AD (1st author) wrote the first draft of the manuscript. AM, PS, MG wrote sections of the manuscript. All authors contributed to manuscript revision and read and approved the submitted version.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Kiran RP, Pokala N, Dudrick SJ. Incidence pattern and survival for gallbladder cancer over three decades—an analysis of 10,001 patients. Ann Surg Oncol (2007) 14(2):827–32. doi: 10.1245/s10434-006-9224-4

2. Gallbladder factsheet (2020). Available at: https://gco.iarc.fr/today/data/factsheets/cancers/12-Gallbladder-fact-sheet.pdf.

3. Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol (2009) 20(1):146–59. doi: 10.1093/annonc/mdn533

4. Goetze TO, Paolucci V. Adequate extent in radical re-resection of incidental gallbladder carcinoma: analysis of the German registry. Oncol Rep (2010) 24(9):2156–64. doi: 10.1007/s00238-010-0914-4

5. Eli Lilly. Gemzar product information. Available at: https://pi.lilly.com/us/gemzar.pdf.

6. Eudaly JA, Tizzano JP, Higdon GL, Todd GC. Developmental toxicity of gemcitabine, an antimetabolite oncolytic, administered during gestation to CD-1 mice. Teratology. (1993) 48(4):365–81. doi: 10.1002/tera.1420480410

7. Collins K, Dong R, Rozenshteyn F, Lung E. 1328 intrauterine pregnancy complicated by a distal common bile duct mass: An unlikely diagnosis of extrahepatic cholangiocarcinoma with intrahepatic metastasis. Off J Am Coll Gastroenterol (AGA) (2019) 114:5735. doi: 10.14309/01.ag.0000594840.35200.8d

8. Botha MH, Rajaram S, Karunaratne K. Cancer in pregnancy. Int J Gynecol Obstet (2018) 143(52):137–42. doi: 10.1002/ijgo.12621

9. Boussios S, Moschetta M, Tatsi K, Tsiouris AK, Pavlidis N. A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives. J Adv Res (2018) 12:1–9. doi: 10.1016/j.jare.2018.02.006

10. Agarwal AK, Kalayarasan R, Javed A, Gupta N, Nag HH. The role of staging laparoscopy in primary gallbladder cancer—an analysis of 409 patients: A prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer. Ann Surg (2013) 258(2):318–23. doi: 10.1097/SLA.0b013e318271497e

11. Peccatori FA, Azim HAJr., Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 24:v160–70. doi: 10.1093/annonc/mdt199

12. Khazaka A, Rasy E, Sleiman Z, Boussios S, Pavlidis N. Systematic review of fetal and placental metastases among pregnant patients with cancer. Cancer Treat Rev (2022) 104:102356. doi: 10.1016/j.ctrv.2022.102356

13. Kim JH, Kim HS, Sung CW, Kim KJ, Kim CH, Lee KY. Descetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy. Lung Cancer (2008) 59(2):270–3. doi: 10.1016/j.lungcan.2007.06.017

14. Gurumurthy M, Koh P, Singh R, Bhude A, Satodia P, Hocking M, et al. Metastatic non-small-cell lung cancer and the use of gemcitabine during pregnancy. J Perinatol (2009) 29(1):63–5. doi: 10.1038/jp.2008.128

15. Lubner S, Hall B, Gopal D, Soni A, Hegeman R, Winterle N, et al. A 37-year-old pregnant woman with pancreatic adenocarcinoma treated with surgery and adjuvant chemotherapy: A case report and literature review. J Gastroint Oncol (2011) 2(4):258–61. doi: 10.3978/j.issn.2078-6891.2011.033

16. Wiesweg M, Aydin S, Koening A, Stein A, Schara U, van Roey C, et al. Administration of gemcitabine for metastatic adenocarcinoma during pregnancy: A case report and review of the literature. AJP Rep (2014) 4(01):017–22. doi: 10.1055/s-0034-1368091

17. Steinberg A, Park D, Parker J, Garvey A, Scigliano E, Strong N. HL-284: First documented use of liposomal doxorubicin in a pregnant patient with Hodgkin lymphoma. Clin Lymphoma Myeloma Leukemia (2020) 20:S248. doi: 10.1016/j.clml.2020.03.009

18. Briggs GG, Towers CV, Forinash AB. Briggs Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th edition ed. Philadelphia, PA: Lippincott Williams & Wilkins (2022).

19. Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol (2012) 13(3):256–64. doi: 10.1016/S1470-2045(11)70383-1